Last reviewed · How we verify

NCT03196245: Flu vaccine

NK Cell Mediated Influenza Immunity During Pregnancy

Terminated Last updated 14 July 2023
What this trial tests

trial testing There is no intervention. in Pregnancy Related in 94 participants. Terminated before completion.

Timeline
14 August 2012
Primary endpoint
1 April 2019
1 April 2019

Quick facts

Lead sponsorStanford University
StatusTerminated
Study typeOBSERVATIONAL
Enrollment94
Start date14 August 2012
Primary completion1 April 2019
Estimated completion1 April 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

Adults 18 to 45, female only, with Pregnancy Related or Influenza, Human. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pregnant women have increased morbidity and mortality due to infection with influenza. Changes in T cell function have been proposed as possible mechanisms for this finding. We believe that pregnancy induced changes in NK cell phenotype and function also impact influenza immunity. This study will compare the immune response of pregnant women and controls to TIV influenza vaccination as a surrogate for infection. In addition pregnant women with flu like illness will be enrolled to evaluate changes in immune response following influenza infection as compared to vaccination.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of There is no intervention.

Trials testing the same drug.

Other recruiting trials for Pregnancy Related

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03196245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing